North Columbus News

U.S. Representatives Mike Carey (R-Ohio-15) and Danny K. Davis (D-Ill.-07) have reintroduced the Patient Access to Innovative New Technologies (PAINT) Act, aiming to reduce regulatory barriers for Medicare beneficiaries seeking access to new medical treatments. Both lawmakers are members of the House Ways and Means Committee.

Rep. Carey emphasized America's leadership in medical innovation, stating that patients' access to care should not be hindered by bureaucratic obstacles. "Our legislation makes it easier for Medicare recipients to take advantage of the newest treatments without bureaucratic delay," he said.

Rep. Davis highlighted the importance of providing manufacturers with a clear path to introduce new medical technologies to patients.

Scott Whitaker, President and CEO of AdvaMed, expressed gratitude towards Congressmen Carey and Davis for their efforts in improving the payment process for innovative medtech solutions.

Mark Leahey, President and CEO of MDMA, praised the bipartisan leadership shown by Reps. Carey and Davis in enhancing CMS’ New Technology Add-on Payment program.

Chris Toth, CEO of Vantive, underscored the importance of timely access to breakthrough technologies for patients facing critical healthcare challenges.

The PAINT Act proposes changes to the Medicare New Technology Add-on Payment (NTAP) Program by requiring CMS to expand its conditional approval pathway. This would include all FDA-approved or cleared technologies through the Breakthrough Device Program, creating a single deadline for alternative pathway products. The goal is to prevent disruptions in access and improve health outcomes by increasing accessibility to care.